04:42 PM EDT, 08/04/2025 (MT Newswires) -- BioMarin Pharmaceutical ( BMRN ) reported Q2 non-GAAP earnings Monday of $1.44 per diluted share, up from $0.96 a year earlier.

Analysts polled by FactSet expected $1.05.

Revenue for the quarter ended June 30 was $825 million, up from $712 million a year earlier.

Analysts surveyed by FactSet expected $761.7 million

The company said it now expects 2025 non-GAAP EPS between $4.40 and $4.55, up from the previous guidance of $4.20 to $4.40, and 2025 revenue between $3.13 billion and $3.2 billion, compared with the previous guidance of $3.1 billion to $3.2 billion.

Analysts polled by FactSet expect $4.32 and $3.14 billion.

The company's shares were rising past 4% in recent after-hours activity.